Alere BinaxNOW®
Medical professionals around the world use BinaxNOW® rapid in vitro diagnostic tests to identify a variety of infectious diseases at the point of care. Our technologies detect bacteria and viruses causing upper and lower respiratory tract infections, including Legionnaires' disease, pneumonia, RSV and influenza, as well as pathogens causing filariasis and malaria.
Rapid and accurate test results provide the foundation for pathogen-specific diagnosis, facilitating optimal patient management and infection control practices.
Accurately read and interpret your Alere BinaxNOW® Influenza A & B, S. pneumoniae & Legionella lateral flow tests in just seconds, delivering automated, objective results in any healthcare setting.
Accurately read and interpret your Alere BinaxNOW® S. pneumoniae & Legionella lateral flow tests in just seconds, delivering automated, objective results in any healthcare setting.
BinaxNOW® Influenza A & B is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab samples.
Alere BinaxNOW® Legionella Urinary Antigen Test is a rapid assay for the qualitative detection of Legionella pneumophila serogroup 1 antigen in urine samples from patients with symptoms of pneumonia.
Alere BinaxNOW® S. pneumoniae is a rapid assay for the qualitative detection of S. pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid (CSF) of patients with meningitis.
The BinaxNOW® Filariasis is an in vitro immunodiagnostic test used to detect Wuchereria bancrofti antigen in whole blood, serum, or plasma.
Alere BinaxNOW® Legionella Urinary Antigen Test is a rapid assay for the qualitative detection of Legionella pneumophila serogroup 1 antigen in urine samples from patients with symptoms of pneumonia.
Binax™ Legionella Urinary Antigen EIA kit is an enzyme immunoassay (EIA) based system intended to qualitatively detect the presence of Legionella pneumophila serogroup 1 antigen in urine as an adjunct to culture for the presumptive diagnosis of past or current Legionnaires’ disease.
The BinaxNOW® Malaria test is an in vitro immunochromatographic assay for the qualitative detection of Plasmodium antigens circulating in human venous and capillary EDTA whole blood of individuals with signs and symptoms of malarial infection.
Alere BinaxNOW® RSV is an in vitro rapid immunochromatographic assay used to detect respiratory syncytial virus (RSV) fusion protein antigen in nasal wash and nasopharyngeal (NP) swab specimens from symptomatic patients.
The BinaxNOW® Strep A Test is a rapid immunochromatographic assay for the qualitative detection of Streptococcus pyogenes Group A antigen from throat swab specimens to aid in the diagnosis of Group A pharyngitis.
Alere BinaxNOW® S. pneumoniae is a rapid assay for the qualitative detection of S. pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid (CSF) of patients with meningitis.
Alere BinaxNOW® Influenza A & B is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab, nasal swab samples and nasal wash/aspirate specimens.
The BinaxNOW® G6PD Test is a visual screening test used for differentiating normal from deficient G6PD activity levels in whole blood and is intended to aid in the identification of people with G6PD deficiency.
BinaxNOW® Legionella Urinary Antigen Test is a rapid assay for the qualitative detection of Legionella pneumophila serogroup 1 antigen in urine samples from patients with symptoms of pneumonia.
BinaxNOW® S. pneumoniae is a rapid assay for the qualitative detection of S. pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid (CSF) of patients with meningitis.
BinaxNOW® RSV is an in vitro rapid immunochromatographic assay used to detect respiratory syncytial virus (RSV) fusion protein antigen in nasal wash and nasopharyngeal (NP) swab specimens from symptomatic patients.
Slowing antibiotic resistance through rapid diagnostics
As microbes become more resilient to antibiotics, common diseases and infections are becoming harder to treat. Before long, operations like organ transplants and C-sections could be too risky to perform. What does that mean to the future of medicine?
